Lab Test

Cannabinoids Urine Level

Urine Cannabinoids Screen, Marinol, Dronabinol (THC), Marijuana, Hashish, Grass, MaryJane, Pot, THC, Hash, hemp, Ganga

Test Codes

EPIC: LAB3585, XCNNCG

Department

Send Outs

Specimen Collection Criteria

Collect: 50 mL random urine in a screw-capped container (preferred) or other sterile collection cup with no preservative. (Minimum: 30 mL)

  • Refrigerate the specimen immediately after collection.
  • Record the exact time of specimen collection on the container or in the computer system.

Physician Office/Draw Specimen Preparation

Maintain specimen refrigerated (2-8°C or 36-46°F) prior to transport.

Preparation for Courier Transport

Transport: 50 mL urine, refrigerated (2-8°C or 36-46°F). (Minimum: 30 mL)

Rejection Criteria

  • Specimens not collected and processed as indicated.
  • Urine Vacutainer® tubes. Urine received in a glass or plastic tube with a rubber stopper may contain insufficient sample volume, preclude confirmatory testing, and give rise to contaminants and artifacts. 

In-Lab Processing

Analyze specimen immediately upon receipt in the Laboratory.

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 7 days
Frozen (-20°C/-4°F or below): 3 months

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days

Laboratory

Sent to ARUP Laboratories, Salt Lake City, UT.

Performed

Results available within 36 hours.

Test Methodology

Gas Chromatography/Mass Spectrometry (GC/MS).
NOTE: Confirmation performed at ARUP Reference Laboratory. 

The confirmation component of this test was developed by Beaumont Health. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes and should not be regarded as investigational or for research.

Interpretation

Drugs identified: Arup: 11-Nor-9-carboxy-THC

Concentrations of drugs and/or metabolite(s) detected in urine have not been correlated to drug levels in the bloodstream or with the degree of impairment. The presence of a drug and/or metabolite(s) in urine is only an indication of previous drug exposure.

Effective June 4, 2019, the laboratory will no longer automatically perform confirmation testing on positive THC screens in patients 21 years of age of older. If confirmation is needed, please call the lab to add the test on to the original specimen.

Clinical Utility

This assay is used to aid in the diagnosis and treatment of cannabinoid use or abuse. This assay provides a preliminary analytical result Positive results are confirmed by chromatographic methods. The primary psychoactive component of marijuana is delta-9-tetra-hydrocannabinol (THC). The THC concentration determines the potency of the marijuana. THC primarily affects the cardiovascular and central nervous systems. There is no reliable method for predicting the degree of impairment from cannabinoid concentrations measured in urine at this time.

CPT Codes

80349

LOINC: 18282-4, 8172-9

Contacts

Last Updated

10/17/2024

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.